Compare Fresenius Kabi Onco. with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs J.B.CHEMICALS - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. J.B.CHEMICALS FRESENIUS KABI ONCO./
J.B.CHEMICALS
 
P/E (TTM) x 22.1 16.3 135.4% View Chart
P/BV x 3.1 2.3 137.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   J.B.CHEMICALS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
J.B.CHEMICALS
Mar-18
FRESENIUS KABI ONCO./
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs176363 48.5%   
Low Rs79255 30.8%   
Sales per share (Unadj.) Rs37.7169.1 22.3%  
Earnings per share (Unadj.) Rs5.116.6 30.7%  
Cash flow per share (Unadj.) Rs6.723.4 28.7%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs42.5172.5 24.7%  
Shares outstanding (eoy) m158.2383.57 189.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.41.8 184.8%   
Avg P/E ratio x25.018.6 134.2%  
P/CF ratio (eoy) x18.913.2 143.4%  
Price / Book Value ratio x3.01.8 166.9%  
Dividend payout %012.0 0.0%   
Avg Mkt Cap Rs m20,13525,827 78.0%   
No. of employees `0001.23.8 30.5%   
Total wages/salary Rs m7032,511 28.0%   
Avg. sales/employee Rs Th5,176.23,747.4 138.1%   
Avg. wages/employee Rs Th610.4665.7 91.7%   
Avg. net profit/employee Rs Th699.6367.8 190.2%   
INCOME DATA
Net Sales Rs m5,96314,135 42.2%  
Other income Rs m18366 4.9%   
Total revenues Rs m5,98114,501 41.2%   
Gross profit Rs m1,4302,178 65.7%  
Depreciation Rs m258570 45.3%   
Interest Rs m-2635 -74.5%   
Profit before tax Rs m1,2161,940 62.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342552 62.0%   
Profit after tax Rs m8061,387 58.1%  
Gross profit margin %24.015.4 155.6%  
Effective tax rate %28.128.5 98.8%   
Net profit margin %13.59.8 137.7%  
BALANCE SHEET DATA
Current assets Rs m5,10210,470 48.7%   
Current liabilities Rs m2,3852,749 86.8%   
Net working cap to sales %45.654.6 83.4%  
Current ratio x2.13.8 56.2%  
Inventory Days Days15055 271.8%  
Debtors Days Days11378 145.9%  
Net fixed assets Rs m5,1485,811 88.6%   
Share capital Rs m158167 94.7%   
"Free" reserves Rs m6,55614,248 46.0%   
Net worth Rs m6,73214,416 46.7%   
Long term debt Rs m9520-   
Total assets Rs m10,38817,649 58.9%  
Interest coverage x-45.856.6 -80.9%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.8 71.7%   
Return on assets %7.58.1 93.2%  
Return on equity %12.09.6 124.4%  
Return on capital %14.613.7 106.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2986,164 85.9%   
Fx outflow Rs m1,7721,334 132.8%   
Net fx Rs m3,5254,829 73.0%   
CASH FLOW
From Operations Rs m1,2741,231 103.5%  
From Investments Rs m-1,204-208 578.7%  
From Financial Activity Rs m-196-595 32.9%  
Net Cashflow Rs m-126427 -29.6%  

Share Holding

Indian Promoters % 0.0 55.4 -  
Foreign collaborators % 81.0 0.3 27,000.0%  
Indian inst/Mut Fund % 0.3 3.4 8.8%  
FIIs % 9.6 3.9 246.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 37.0 24.6%  
Shareholders   42,599 30,437 140.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   FDC LTD.  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

J.B.CHEMICALS 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of J.B.CHEMICALS for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of J.B.CHEMICALS. Also includes updates on the valuation of J.B.CHEMICALS.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS